Search results for "Coste"

showing 10 items of 368 documents

Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet (R)) versus calcipotriol (Daivonex (R)) in the treatment of …

2007

Objective: A clinical trial was performed to evaluate the efficacy, speed of response, side effects and quality of life of patients treated with calcipotriol/betamethasone dipropionate (Dovobet (R)) for 4 weeks followed by maintenance with calcipotriol for 8 weeks (group A) versus calcipotriol (Daivonex (R)) alone for 12 weeks (group B) for the treatment of psoriasis. Materials and methods: A total of 150 patients were enrolled and randomized to groups A and B. PASI and Skindex-29 were considered the outcome measures. Results: Ninety-six patients completed the trial. At weeks 2 and 4, both groups showed a significant clinical improvement compared to baseline; group A demonstrated a higher c…

AdultMalemedicine.medical_specialtyRandomizationAdolescentskindex-29medicine.drug_classBetamethasone dipropionatecalcipotriol/betamethasone dipropionate; Dovobet; calcipotriol. Daivonex; psoriasis vulgaris; clinical trialDermatologyAdministration CutaneousBetamethasoneSeverity of Illness IndexDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialCalcitriolcalcipotriolo/betametasone dipropionatolawPsoriasisInternal medicinepasimedicineHumansPsoriasiscalcipotriolo; calcipotriolo/betametasone dipropionato; pasi; psoriasi; skindex-29CalcipotriolcalcipotriolopsoriasiAgedAged 80 and overAnalysis of Variancebusiness.industrycalcipotriol calcipotriol/betamethasone dipropionate PASI psoriasis Skindex-29 two-compound productMiddle Agedmedicine.diseaseSurgeryClinical trialDrug CombinationsTreatment OutcomechemistryQuality of LifeCorticosteroidBetamethasoneFemaleDermatologic Agentsbusinessmedicine.drug
researchProduct

Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus.

2008

Background Oral lichen planus (OLP) is considered to be an autoimmune disease of unknown aetiology that affects the mucosae, especially the oral cavity. Objective We compared tacrolimus 0.1% ointment and clobetasol 0.05% ointment for the treatment of OLP. Patients and methods A total of 32 patients (20 females and 12 males; all white, Italian origin, mean age of 43.6+/-18.4 years; 16 patients per treatment group) were treated with tacrolimus or clobetasol ointment for 4 weeks in a randomized, double-blind, clinical trial. Pain severity, burning sensation, and mucosal lesion extension were assessed using a four-point scale. Results At the end of the treatment period, symptom scores were sign…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.drug_classAnti-Inflammatory Agentstacrolimus ointment; clobetasol ointment; oral lichen planuslaw.inventionOintment Basesoral lichen planusRandomized controlled triallawOral administrationFacial PainmedicineHumanstacrolimus ointmentSalivatacrolimusbusiness.industryclobetasol ointmentclobetasol; tacrolimus; oral lichen planusmedicine.diseaseDermatologyTacrolimusCalcineurinstomatognathic diseasesclobetasolOintment BasesPeriodonticsCorticosteroidOral lichen planusFemaleClobetasol propionatebusinessEpidemiologic MethodsImmunosuppressive Agentsmedicine.drugLichen Planus Oral
researchProduct

Duration of immunosuppressive therapy in autoimmune hepatitis

2001

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentMEDLINEAutoimmune hepatitisGastroenterologyRemission inductionRecurrenceInternal medicinemedicineHumansChildAgedAutoimmune diseaseHepatitisChemotherapyHepatologybusiness.industryRemission InductionMiddle Agedmedicine.diseaseHepatitis AutoimmuneImmunologyCorticosteroidFemalebusinessImmunosuppressive AgentsJournal of Hepatology
researchProduct

Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study.

1990

Abstract The influence of ciamexone on the activity and course of endocrine orbitopathy was investigated. Fifty-one patients with active orbitopathy classes II-VI were allocated randomly to two groups: over a period of six months, 26 patients received 300 mg/day ciamexone and 25 patients received placebo tablets. In both groups, prednisolone was administered in addition in the first four weeks. Ophthalmological investigations and clinical tests as well as orbit sonography were carried out before as well as one, three and six months after the beginning of therapy. Before and after treatment, computer tomography of the orbit was performed. Symptoms and signs did not show any significant impro…

AdultMalemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEye diseasePrednisoloneAziridinesPlacebo-controlled studyVisual AcuityPlaceboRandom AllocationEndocrinologyAdjuvants ImmunologicDouble-Blind MethodInternal medicineOrbital DiseasesMedicineHumansExophthalmusIntraocular PressureAgedChemotherapybiologybusiness.industryThyroiditis AutoimmuneEndocrine orbitopathyGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseEndocrinologyPrednisoloneCorticosteroidFemalebusinessmedicine.drugActa endocrinologica
researchProduct

Ciclosporin and thyroid-stimulating immunoglobulins in endocrine orbitopathy.

1989

The study investigated whether ciclosporin (C) affected the thyroid-stimulating immunoglobulins (TSI) in serum of patients with endocrine orbitopathy (EO). The effect of C was compared with that of prednisone (P). Fifteen patients with EO classes III-V received C (n = 7) or P (n = 8). In addition to the immunosuppressants, five patients with Graves' disease in each group received methimazole (MMI). The stimulation of the cAMP levels in the medium of thyrocyte cultures was determined as a parameter of TSI. The TSI levels were markedly lowered in both groups during and after therapy. C group: before therapy 6.2 pmol/ml +/- 1.63 (100%, mean +/- SEM), during treatment 4.6 pmol/ml +/- 2.28 (74%)…

AdultMalemedicine.medical_specialtymedicine.drug_classGraves' diseasemedicine.medical_treatmentThyroid GlandCyclosporinsPrednisoneInternal medicinemedicineCyclic AMPExophthalmosHumansAgedChemotherapyTriiodothyronineMethimazolebusiness.industryThyroidGeneral MedicineMiddle Agedmedicine.diseaseCiclosporinGraves DiseaseTiterEndocrinologymedicine.anatomical_structureImmunoglobulin GCorticosteroidPrednisoneTriiodothyronineFemalebusinessmedicine.drugImmunoglobulins Thyroid-StimulatingResearch in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie
researchProduct

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double-Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

2018

Objective: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline. Methods: In this phase III, double-blind, placebo-controlled study (BEL112341; ClinicalTrials.gov identifier: NCT01484496), patients with moderate to severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index [SELENA–SLEDAI] score ≥8) were randomized (2:1) to receive weekl…

AdultMalemedicine.medical_specialtymedicine.drug_classInjections SubcutaneousPopulationImmunologyPlaceboAntibodies Monoclonal HumanizedGastroenterologySystemic Lupus ErythematosusSeverity of Illness Index03 medical and health sciences0302 clinical medicineDouble-Blind MethodRheumatologyInternal medicinemedicineHumansLupus Erythematosus SystemicImmunology and Allergy030212 general & internal medicineeducationAdverse effectskin and connective tissue diseases030203 arthritis & rheumatologyeducation.field_of_studyLupus erythematosusIntention-to-treat analysisbusiness.industryComplement C3DNAmedicine.diseaseBelimumabRheumatologyIntention to Treat AnalysisTreatment OutcomeAntibodies AntinuclearImmunology and Allergy; Rheumatology; ImmunologyCorticosteroidOriginal ArticleFemalebusinessmedicine.drug
researchProduct

Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics.

2005

Background:  Several in vitro studies demonstrate that corticosteroids and long-acting β2 agonists may have a complementary and synergistic mode of action on the inflammatory processes in asthma. Methods:  Sputum was induced in 20 mild to moderate asthmatic patients and the induced sputum cells (ISC) were cultured with beclomethasone dipropionate (BDP) 10−7 M, salbutamol 10−8 M and formoterol 10−8 M either alone or in combination, BDP plus salbutamol and BDP plus formoterol, for 24 h. We measured the levels of growth macrophages-colony stimulating factor (GM-CSF), released on activation normal T cells expressed and activated (RANTES) and interleukin-8 (IL-8), in the supernatant of stimulate…

AdultMalemedicine.medical_specialtymedicine.drug_classReceptor expressionImmunologySeverity of Illness IndexGlucocorticoid receptorReceptors GlucocorticoidInternal medicineFormoterol FumaratemedicineImmunology and AllergyHumansAlbuterolDrug InteractionsTissue DistributionAnti-Asthmatic AgentsChemokine CCL5Cells Culturedbusiness.industryInterleukin-8BeclomethasoneSputumGranulocyte-Macrophage Colony-Stimulating FactorBeclometasone dipropionaterespiratory systemMiddle AgedAsthmarespiratory tract diseasesBronchodilator AgentsEndocrinologyEthanolaminesSalbutamolCorticosteroidFormoterol FumarateDrug Therapy CombinationFemaleFormoterolReceptors Adrenergic beta-2businessEx vivomedicine.drugAllergy
researchProduct

Evaluation of socket healing in patients undergoing bisphosphonate therapy: experience of a single Institution

2012

Objective: To assess the clinical features of exodontias performed in cancer patients who have been receiving intravenous bisphosphonates (BPs). Study Design: This is a retrospective cohort study using a sample of 20 patients receiving BPs who had 62 teeth extracted. An univariate analysis was applied to calculate socket healing time (HT), comparing among exodontias performed according to cause, such as periodontal disease or caries, type of BP, and use of corticosteroid. In order to analyze the influence of each variable on HT, multiple statistical analyses were performed through logistic multiple regression. Results: From the 62 tooth extractions performed, 5 exodontias had evolved to 4 s…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentDentistryOdontologíaCohort StudiesmedicineHumansTooth SocketGeneral DentistryDental alveolusAgedRetrospective StudiesAged 80 and overUnivariate analysisWound HealingDiphosphonatesbusiness.industryCancerRetrospective cohort studyBisphosphonateMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryOtorhinolaryngologyTooth ExtractionUNESCO::CIENCIAS MÉDICASCorticosteroidSurgeryFemaleResearch-ArticleOdontostomatology for the Disabled or Special PatientsbusinessOsteonecrosis of the jawCohort study
researchProduct

SQ HDM SLIT-tablet (ALK) in treatment of asthma – Post hoc results from a randomised trial

2014

SummaryIntroductionIn a double-blind, placebo-controlled trial (EudraCT identifier: 2006-001795-20), the standardised quality (SQ) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (ALK, Denmark) was investigated.MethodThe trial included 604 subjects, ≥14 years, with mild-moderate HDM allergic asthma. Subjects were randomised 1:1:1:1 to 1, 3 or 6 SQ-HDM or placebo once daily. The primary endpoint was reduction in inhaled corticosteroid (ICS) after one year. ICS reduction, asthma quality of life questionnaire (AQLQ) and asthma control questionnaire (ACQ) score was analysed post hoc in a subgroup with daily ICS use of 400–800 μg and ACQ score of 1–1.5, corresponding to partly contr…

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtymedicine.drug_classPopulationPlaceboHouse dust miteDouble-Blind MethodQuality of lifeSurveys and QuestionnairesmedicineClinical endpointAnimalsHumansSLIT-tabletBudesonideeducationGlucocorticoidsICS reductionAsthmaHouse dust miteSublingual Immunotherapyeducation.field_of_studybiologybusiness.industryPyroglyphidaemedicine.diseasebiology.organism_classificationAsthma; Asthma quality of life; House dust mite; ICS reduction; SLIT-tabletAsthmaTreatment OutcomeAsthma Control QuestionnaireQuality of LifeCorticosteroidAsthma quality of lifebusinessTabletsRespiratory Medicine
researchProduct

Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.

1991

Hirsutism in women is often explained on the basis of abnormal peripheral androgen metabolism. To determine whether serum markers of ovarian, adrenal, or peripheral androgen production may be helpful determinants in the treatment of hirsutism and to compare the efficacy of treatment with dexamethasone or spironolactone, 20 hyperandrogenic hirsute patients were treated for up to 2 years. Eleven women who were selected on the basis of sensitivity to dexamethasone were treated with a daily dose of 0.37 mg dexamethasone and had androgen levels suppressed into the normal range. Although significant (P less than .05), Ferriman-Gallwey scores decreased only by 20%: 14.2 +/- 0.5 to 11.4 +/- 0.6. Ni…

Adultmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classmedicine.medical_treatmentSpironolactoneAndrogen suppressionAntiandrogenAndrosteroneDexamethasonechemistry.chemical_compoundInternal medicinemedicineHumansTestosteronehirsutismDexamethasoneChemotherapybusiness.industryDehydroepiandrosterone SulfateAndrostenedioneObstetrics and GynecologyAndrogen AntagonistsDihydrotestosteroneGeneral MedicineDehydroepiandrosteroneAndrogenmedicine.diseaseAndrostane-317-diolDrug CombinationsEndocrinologychemistrySpironolactoneAndrogensCorticosteroidFemalebusinessmedicine.drugObstetrics and gynecology
researchProduct